YMAB YmAbs: Market Capitalization to Book Value Ratio
Y-mAbs Therapeutics (YMAB) ensures the express delivery of radiopharmaceuticals through a network of nuclear centers, maintaining high margins. Reliable temperature control during the transportation of pediatric medicines guarantees their safety. The brand is renowned for developing targeted antibodies, as confirmed by the 4.44 metric. The company's market trend on the GURU.Markets platform visualizes the asset value dynamics of this manufacturer.
%20-%20Market%20Cap%20to%20Net%20Assets%20Ratio&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_YMAB_-_Y-mAbs-Therapeutics_-_Market-Cap-to-Net-Assets-Ratio "YMAB YmAbs Market Capitalization to Book Value Ratio (07/04/2022 - 09/27/2025) | 👁️GURU.Markets👁️")
YMAB (Y-mAbs Therapeutics Inc): analytical breakdowns and indicator data
Y-mAbs Therapeutics (YMAB) maintains a monopoly status in pediatric oncology due to exclusive FDA approvals and orphan drug designations. By analyzing the current market-to-book ratio on GURU.Markets, an investor assesses the market price premium over equity, which helps determine the extent of the overpayment for the company's intellectual property and the overall resilience of the share price to corrections.